RxDoctor Payments Data

Richard Zweifler, MD

Vascular Neurology · New Orleans, LANPI 1295774347

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (46.5%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Bayer at 42.5% of the total. 2023 is the largest year on record at $3,079, 4.9 times the $631 reported in 2019.

$4,742in general payments, 2019–2025

Across 62 payments — averaging $76.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$2K
  • Medtronic$955
  • Janssen Research & Development, LLC$862
  • E.r. Squibb & Sons, L.L.C.$246
  • Amgen$142
  • AbbVie$91
  • plus $431 from 13 others
$312,804in research payments, 2019–2025

Across 68 payments — averaging $4600.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Medtronic$114K
  • E.r. Squibb & Sons, L.L.C.$110K
  • Janssen Research & Development, LLC$72K
  • Boehringer Ingelheim$9K
  • Bayer$8K

What the payments were for

  • Consulting fees$75016%
  • Speaking & faculty fees$230%
  • Travel & lodging$2,20747%
  • Food & beverage$1,67135%
  • Education$912%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular neurology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$21,910
Medicare patients
110
Services billed
176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant13$12,932
Nurtec OdtRimegepant Sulfate11$10,832
Gabapentin55$529
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine20$483
Topiramate18$456
Tizanidine Hcl29$435
Trazodone Hcl19$304
Sumatriptan Succinate14$206
Atorvastatin Calcium26$197
Donepezil Hcl30$183
Amitriptyline Hcl13$148
Ondansetron Hcl12$82
Escitalopram Oxalate11$69

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$91$12,93213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular neurology providers in Louisianaon file to place this against a meaningful peer group, so we don't.

Other vascular neurology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →